Foundayo vs Tirzepatide: An Oral GLP-1 Pill Against a Weekly Dual Agonist

Foundayo (orforglipron) is a once-daily oral small-molecule GLP-1 receptor agonist approved by the FDA on April 1, 2026. Tirzepatide, sold as Zepbound for weight management and Mounjaro for type 2 diabetes, is a once-weekly subcutaneous injection that acts at both the GLP-1 and GIP receptors.

In their respective 72-week phase 3 obesity trials, the highest orforglipron dose produced a mean weight reduction of 11.2 percent, while the highest tirzepatide dose produced 20.9 percent. Those numbers come from different trials in different populations, so they describe two separate results rather than a measured difference between the drugs.

The choice between an oral GLP-1 and an injectable dual agonist is one of the few decisions in weight management where format and potency pull in opposite directions. A patient who will not inject cannot benefit from the more potent option at all, which makes the smaller average effect of a pill the relevant number for that person rather than a disappointment.

It also matters because the gap between the two is frequently overstated in both directions. Marketing tends to flatten the difference; skeptics tend to dismiss the pill. The trial data support neither framing.

Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor. Because it is not a peptide, it survives digestion well enough to be taken as an ordinary tablet with or without food and without the water and fasting restrictions that apply to oral semaglutide. It requires no refrigeration and no injection technique, which removes two of the most common reasons patients decline or abandon incretin therapy.

Tirzepatide is a peptide that must be injected subcutaneously once weekly. It is a dual agonist, acting at both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor. The second pathway is the most credible pharmacologic explanation for why tirzepatide has produced larger average weight reductions than single-pathway GLP-1 agonists in trials, though mechanism alone does not settle efficacy.

Approved dosing differs accordingly. Foundayo starts at 0.8 mg once daily and escalates at intervals of at least 30 days through 2.5, 5.5, 9, 14.5, and 17.2 mg, with 17.2 mg as the maximum. Tirzepatide is titrated over weeks from 2.5 mg weekly toward maintenance doses of 5, 10, or 15 mg.

ATTAIN-1, published in the New England Journal of Medicine in 2025, randomized 3,127 adults with obesity and without diabetes to orforglipron 6 mg, 12 mg, or 36 mg, or placebo, for 72 weeks. Mean weight change was minus 7.5 percent, minus 8.4 percent, and minus 11.2 percent across the three doses, against minus 2.1 percent with placebo. In the highest dose group, 54.6 percent of participants lost at least 10 percent of body weight, 36.0 percent lost at least 15 percent, and 18.4 percent lost at least 20 percent.

SURMOUNT-1, published in 2022, randomized 2,539 adults with obesity and without diabetes to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, also for 72 weeks. Mean weight change was minus 15.0 percent, minus 19.5 percent, and minus 20.9 percent, against minus 3.1 percent with placebo. At the 15 mg dose, 57 percent of participants lost at least 20 percent of body weight.

For context on where tirzepatide sits among injectables, SURMOUNT-5 compared it directly with semaglutide in 751 adults with obesity and without diabetes. Tirzepatide produced a mean reduction of 20.2 percent against 13.7 percent for semaglutide at 72 weeks. That trial was open-label, which is a real limitation for a subjective outcome, though body weight itself is measured rather than reported.

No randomized trial has compared orforglipron with tirzepatide. Placing minus 11.2 percent beside minus 20.9 percent is a cross-trial comparison, and cross-trial comparisons are unreliable in proportion to how much the trials differ in baseline weight, population, titration schedule, background lifestyle intervention, and statistical estimand. ATTAIN-1 and SURMOUNT-1 are unusually similar in design, which makes the comparison more informative than most, but it remains indirect evidence.

A living network meta-analysis of diabetes medications published in The BMJ in 2025, covering 869 randomized trials and 493,168 participants, ranked tirzepatide first for weight reduction at a mean difference of minus 8.63 kg and orforglipron second at minus 7.87 kg. Two things in that result deserve attention. The gap between them is far narrower than the obesity trial percentages suggest, and the certainty ratings differ: moderate for tirzepatide, low for orforglipron. Low certainty means the estimate may move substantially as more data arrive.

One practical caution about dose numbers. The tablet strengths approved for Foundayo, 0.8 mg through 17.2 mg, do not correspond to the 6, 12, and 36 mg dose arms reported in ATTAIN-1. Patients comparing products should reason in terms of the trial and the prescribed titration step rather than treating a milligram figure as portable between sources.

Gastrointestinal effects dominate the adverse event profile of both drugs. Nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain are the most commonly reported reactions with orforglipron, and most are mild to moderate and concentrated during dose escalation. The same pattern holds for tirzepatide.

In ATTAIN-1, adverse events led to treatment discontinuation in 5.3 to 10.3 percent of orforglipron participants against 2.7 percent on placebo. In SURMOUNT-1, discontinuation for adverse events occurred in 4.3 to 7.1 percent of tirzepatide participants against 2.6 percent on placebo. Those figures are close enough that neither drug can be presented as clearly gentler on the basis of discontinuation alone.

Severe gastrointestinal events are a different question. In the BMJ network meta-analysis, tirzepatide carried the highest estimated risk of severe gastrointestinal events among the drug classes examined, with an odds ratio of 4.21 and moderate certainty. That is a meaningful signal for a patient with a history of gastroparesis, severe reflux, or prior intolerance of an incretin.

Both carry a boxed warning regarding thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis is a labeled warning for both.

The decision usually resolves on three questions rather than on the headline percentage. First, will this person inject reliably for a year or more? Adherence to a treatment that is refused or abandoned is zero regardless of its trial performance. Second, how much weight reduction does this person actually need to reach the clinical goal, whether that is blood pressure control, sleep apnea severity, glycemic targets, or joint loading? An 11 percent reduction is clinically meaningful for many of those endpoints. Third, what does tolerability history suggest about the ceiling dose this person will reach?

Cost, coverage, and supply belong in the same conversation. A more potent drug that a patient cannot obtain or afford across a full year is not the more effective drug for that patient.

Switching between the two is possible but is not a milligram-for-milligram exchange. The molecules differ, the receptor targets differ, and the titration ladders differ, so a switch should be planned with a fresh escalation schedule rather than a direct substitution.

The within-trial evidence for each drug is strong. Both ATTAIN-1 and SURMOUNT-1 are large, randomized, placebo-controlled, 72-week phase 3 trials with prespecified estimands and intention-to-treat analysis. For the question of whether each drug outperforms placebo, and by roughly how much, the answer is settled.

The between-drug evidence is weak by comparison. It rests on indirect comparison across trials and on a network meta-analysis conducted in a type 2 diabetes population rather than an obesity population. Indirect evidence of this kind is useful for ordering options and poor for quantifying the size of a difference.

Both pivotal trials were funded by the manufacturer of the drug under study, which is the norm in this field and still worth stating plainly. SURMOUNT-5 was open-label, which introduces the possibility that behavior differed between arms even though weight itself was objectively measured.

The network meta-analysis that places the two drugs closest together studied medications in adults with type 2 diabetes. Weight response to incretins is generally smaller in type 2 diabetes than in obesity without diabetes, so those kilogram figures should not be read as obesity-trial equivalents.

Orforglipron entered clinical use recently. Long-term maintenance data, cardiovascular outcome data, and post-marketing safety experience are all thinner for it than for tirzepatide, and thin post-marketing experience is a limitation that resolves only with time.

None of this evidence shows that one drug is better for any particular patient. Trials report averages, and the distributions around those averages overlap substantially. A given individual may respond better to the agent with the smaller mean effect.

The trials do not show what happens after the trial ends. They do not establish durability of weight reduction after discontinuation, the consequences of intermittent adherence, or the trajectory of muscle mass and bone density over multiple years on either agent.

They also do not compare the two drugs on hard outcomes that matter more than the scale, including cardiovascular events, incident diabetes, sleep apnea severity, or mortality. Tirzepatide has accumulated more outcome data than orforglipron, but a direct comparison on those endpoints does not exist.

The arrival of a genuinely oral GLP-1 agonist changes the shape of the field more than it changes any individual prescription. Manufacturing capacity for small molecules is not constrained the way peptide manufacturing has been, which is the most plausible route to wider access and lower cost over time. Access, in practice, has limited incretin therapy at least as much as efficacy has.

It also reframes the potency conversation. For several years the question in weight management pharmacology has been how much weight a drug can remove. A pill with a somewhat smaller average effect but far fewer barriers to starting and continuing raises a different question, which is how much weight reduction a population achieves rather than how much a trial completer achieves.

The question I hear is almost never framed as a pharmacology question. It is framed as whether the pill is a compromise. My answer is that it is a trade, not a compromise, and the trade is only worth making if the thing being traded away matters less to that patient than what is being gained.

For a patient who has already declined injections twice, the comparison with tirzepatide is academic. For a patient with severe obstructive sleep apnea who needs a large reduction and is comfortable with a weekly injection, I would not start with the pill and hope. The pharmacology is the easy part of this conversation. Matching the option to the person is the work.

I would also caution against reading percentage figures across trials as though they were measured against each other. They were not. That distinction gets lost quickly in patient-facing material, and it is the difference between an informed choice and a marketing impression.

Tirzepatide has produced larger average weight reduction in its trials than orforglipron has in its own, and no trial has compared them directly. Foundayo’s advantage is that it is a daily tablet with no injection, no refrigeration, and no food or water restriction. Choose on the basis of what the patient will sustain, what reduction the clinical goal requires, and what tolerability history suggests, and revisit the choice rather than treating it as permanent.

Carry forward two things. The first is that both drugs clearly outperform placebo over 72 weeks, and both do so by margins that matter clinically. The second is that the size of the gap between them is not known, because it has never been measured. Treat the 11 percent and 21 percent figures as facts about two separate trials rather than as a scoreboard.